CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II of Gefitinib (IRESSA) Administered as First-line Treatment in Patients With Non-resectable Pneumonic-type Adenocarcinoma (P-ADC)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00198380
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:55.305721+00:00
Published At: 2024-03-08T00:00:00+00:00
Record Updated At: 2024-03-08
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Pneumonic-type Adenocarcinoma (P-ADC)", "Lung Adenocarcinoma With Bronchiolo-alveolar Feature"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-03-08"
protocolSection.identificationModule.nctId: "NCT00198380"
protocolSection.identificationModule.officialTitle: "Phase II of Gefitinib (IRESSA) Administered as First-line Treatment in Patients With Non-resectable Pneumonic-type Adenocarcinoma (P-ADC)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.